Testing Adaptive Stereotactic Radiotherapy in Men With Localized Prostate Cancer
Compares adjusted stereotactic radiotherapy with standard treatment in men with localized prostate cancer.
Plain-language title generated from the registry record
Registry title: Adaptive Stereotactic Radiotherapy for Localized Prostate Cancer
Key facts
- Where
- Saint-Denis, RéunionSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men aged 60 or older with prostate cancer that has not spread and is at low or intermediate risk, who are to have radiotherapy.
- Age
- 60 years or older
- Sex
- Men only
- Disease stage
- Localized prostate cancer of low or intermediate risk (T1-T2), Gleason score 6-7, PSA below 15 ng/mL, no sign of metastatic disease
- Earlier treatment
- No prior surgery on the prostate or the digestive system that could influence the study results. Radiotherapy must be indicated for the prostate cancer.
- Biomarker or test result
- PSA below 15 ng/mL
Main reasons for not taking part
- Cannot read, write or understand French
- Vulnerable patient under the French Public Health Code, or an adult under guardianship or legal protection
- Already in another interventional study that could interfere with the results
- Past prostate or digestive surgery that could influence the results
- Cannot or will not sign the written informed consent
Read by machine on 9 November 2026.
Where in Réunion
- Clinique Sainte ClotildeSaint-Denis, RéunionTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Clinique Sainte Clotilde
- Trial code
- NCT07344844
- Record updated
- 15 January 2026
- Original description
This study evaluates whether adaptive stereotactic body radiotherapy (SBRT) provides dosimetric advantages compared to non-adaptive SBRT in localized prostate cancer. Five low-dose CT scans are performed before each SBRT session to assess anatomical variations (bladder filling, rectal volume) and determine if a dosimetric recalculation would have been required. The study also evaluates cumulative dose to organs at risk, patient-reported quality of life over 24 months, and overall and recurrence-free survival.Read full original descriptionShow less
Intérêt de la radiothérapie Adaptative en stéréotaxie Prostatique
This study evaluates whether adaptive stereotactic body radiotherapy (SBRT) provides dosimetric advantages compared to non-adaptive SBRT in localized prostate cancer. Five low-dose CT scans are performed before each SBRT session to assess anatomical variations (bladder filling, rectal volume) and determine if a dosimetric recalculation would have been required. The study also evaluates cumulative dose to organs at risk, patient-reported quality of life over 24 months, and overall and recurrence-free survival.
Inclusion: Male aged ≥60 years; Localized prostate cancer of low or intermediate risk (T1-T2); Gleason score 6-7; PSA <15 ng/mL; No evidence of metastatic disease; Radiotherapy indicated for prostate cancer; Affiliated with or benefiting from a French social security system; French-speaking patient; Patient appropriately informed and having signed a written informed consent form.
Exclusion: History of urological (prostate) or digestive surgery that could influence study outcomes; Unable to read, write, or understand French; Vulnerable patient as defined by Article L1121-6 of the French Public Health Code; Adult under guardianship, curatorship, or legal protection ("sauvegarde de justice"); Patient unable to personally provide informed consent according to Article L1121-8 of the French Public Health Code; Patient already included in another interventional study that could interfere with study outcomes; Refusal to sign the written informed consent form.